Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Table 1

Patient demographics and clinical backgrounds.

Category or variable	No. (%) or value
No. of patients	50
Gender
Male	34 (68.0)
Female	16 (32.0)
Age (years)
Median	69
Range	41–85
Primary esophageal cancer
Cervical and upper thoracic	8 (16.0)
Middle thoracic	34 (68.0)
Lower thoracic	8 (16.0)
Histology
Squamous cell carcinoma	48 (96.0)
Adenocarcinoma	2 (4.0)
Differentiation
Well	6 (12.0)
Moderate	23 (46.0)
Poor	2 (4.0)
Unknown	19 (38.0)
Metastasis
Yes	36 (72.0)
No	14 (28.0)
Metastatic site
Bone	3 (6.0)
Liver	7 (14.0)
Lung	8 (16.0)
Nonregional lymph node	21 (42.0)
Other	3 (6.0)
Esophagectomy
Yes	28 (56.0)
No	22(44.0)
Prior radiotherapy
Yes	5 (10.0)
No	45 (90.0)
ECOG performance status
0	21 (42.0)
1	29 (58.0)